Understand the source comparison
Peptides Cancer Research: Types Comparison
Receptor-Targeting (RGD, somatostatin) Binds overexpressed tumor receptors Drug delivery, imaging, direct inhibition 10–50× receptor density on cancer cells vs normal tissue Requires precise receptor expression profiling per tumor type Immune-Modulating (PD-L1
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Receptor-Targeting (RGD, somatostatin)
- Binds overexpressed tumor receptors
- Drug delivery, imaging, direct inhibition
- 10–50× receptor density on cancer cells vs normal tissue
- Requires precise receptor expression profiling per tumor type
- Immune-Modulating (PD-L1 blockers)
- Blocks immune checkpoint interactions
- Restores T-cell anti-tumor activity
- Smaller molecule reduces off-target immune activation
- Optimal dosing differs from antibody protocols
- Cell-Penetrating (TAT, penetratin)
- Facilitates membrane crossing
- Delivers therapeutic cargo intracellularly
- Bypasses efflux pumps and membrane barriers
- Non-specific uptake can occur in healthy cells
- Peptide-Drug Conjugates
- Releases cytotoxin after internalisation
- Targeted chemotherapy
- Drug released only inside tumor cells after receptor binding
- Linker stability and premature payload release
- Radiolabelled (theranostics)
- Delivers imaging or therapeutic isotope
- PET imaging and radiotherapy
- Same peptide used for diagnosis and treatment
- Radiation safety, isotope half-life constraints
- Every peptide class shown above requires validation through three sequential checkpoints: binding affinity assays (does it bind the intended target?), internalisation studies (does it enter the cell?), and functional assays (does it produce the intended biological effect?). Skipping any checkpoint risks discovering inefficacy only after expensive in vivo studies have already begun.